Hepatitis B and C in pregnancy: A review and recommendations for care

Journal of Perinatology

Volumn 34, Issue 12, 2014, Pages 882-891

  Dunkelberg, J C ^a   Berkley, E M F ^b   Thiel, K W ^a   Leslie, K K ^a  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^b EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BOCEPREVIR; FUMARIC ACID; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIBODY; LAMIVUDINE; PEGINTERFERON; RIBAVIRIN; TELAPREVIR; TELBIVUDINE; TENOFOVIR DISOPROXIL; VIRUS DNA; ANTIVIRUS AGENT; THYMIDINE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BIRTH INJURY; BREAST FEEDING; CESAREAN SECTION; DIAGNOSTIC APPROACH ROUTE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; FATTY LIVER; FETAL SCALP ELECTRODE; FETUS DISEASE; FETUS MONITORING; FOLLOW UP; GESTATIONAL AGE; HEPATITIS B; HEPATITIS C; HIGH RISK INFANT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPROPHYLAXIS; INFECTION PREVENTION; INFECTION RISK; INTRAUTERINE GROWTH RETARDATION; LACTIC ACIDOSIS; MATERNAL CARE; META ANALYSIS (TOPIC); MIXED INFECTION; NEWBORN CARE; PERINATAL PERIOD; PRACTICE GUIDELINE; PREGNANCY COMPLICATION; PREGNANCY OUTCOME; PREMATURE LABOR; PREPREGNANCY CARE; PROGNOSIS; PROLONGED MEBRANE RUPTURE; SCREENING; TERATOGENICITY; VACCINATION; VERTICAL TRANSMISSION; VIRUS LOAD; VIRUS TRANSMISSION; WITHDRAWAL SYNDROME; ANALOGS AND DERIVATIVES; CONTRAINDICATIONS; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; MASS SCREENING; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREVENTION AND CONTROL; TRANSMISSION; VIREMIA;

ANTIVIRAL AGENTS; BREAST FEEDING; CESAREAN SECTION; DNA, VIRAL; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; LAMIVUDINE; MASS SCREENING; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREGNANCY OUTCOME; THYMIDINE; VIREMIA;

EID: 84926222332     PISSN: 07438346     EISSN: 14765543     Source Type: Journal    
DOI: 10.1038/jp.2014.167     Document Type: Article

References (109)

1. Sorrell MF, Belongia EA, Costa J, Gareen IF, Grem JL, Inadomi JM et al. National Institutes of Health Consensus Development Conference Statement: management of hepatitis B. Ann Intern Med 2009; 150(2): 104-110.
2. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: New estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012; 30(12): 2212-2219.
3. Merrill RM, Hunter BD. Seroprevalence of markers for hepatitis B viral infection. Int J Infect Dis 2011; 15(2): E78-E121.
4. Rustgi VK. The epidemiology of hepatitis C infection in the United States. J Gastroenterol 2007; 42(7): 513-521.
5. Connell LE, Salihu HM, Salemi JL, August EM, Weldeselasse H, Mbah AK. Maternal hepatitis B and hepatitis C carrier status and perinatal outcomes. Liver Int 2011; 31(8): 1163-1170.
6. Reddick KL, Jhaveri R, Gandhi M, James AH, Swamy GK. Pregnancy outcomes associated with viral hepatitis. J Viral Hepat 2011; 18(7): e394-e398.
7. Berkley EM, Leslie KK, Arora S, Qualls C, Dunkelberg JC. Chronic hepatitis C in pregnancy. Obstet Gynecol 2008; 112(2 Pt 1): 304-310.
8. Safir A, Levy A, Sikuler E, Sheiner E. Maternal hepatitis B virus or hepatitis C virus carrier status as an independent risk factor for adverse perinatal outcome. Liver Int 2010; 30(5): 765-770.
9. Tse KY, Ho LF, Lao T. The impact of maternal HBsAg carrier status on pregnancy outcomes: a case-control study. J Hepatol 2005; 43(5): 771-775.
10. Gambarin-Gelwan M. Hepatitis B in pregnancy. Clin Liver Dis 2007; 11(4): 945-963.
11. Lao TT, Chan BC, Leung WC, Ho LF, Tse KY. Maternal hepatitis B infection and gestational diabetes mellitus. J Hepatol 2007; 47(1): 46-50.
12. Pergam SA, Wang CC, Gardella CM, Sandison TG, Phipps WT, Hawes SE. Pregnancy complications associated with hepatitis C: data from a 2003-2005 Washington state birth cohort. Am J Obstet Gynecol 2008; 199(1): 38, e31-e39.
13. Locatelli A, Roncaglia N, Arreghini A, Bellini P, Vergani P, Ghidini A. Hepatitis C virus infection is associated with a higher incidence of cholestasis of pregnancy. Br J Obstet Gynaecol 1999; 106(5): 498-500.
14. Paternoster DM, Fabris F, Palu G, Santarossa C, Bracciante R, Snijders D et al. Intra-hepatic cholestasis of pregnancy in hepatitis C virus infection. Acta Obstet Gynecol Scand 2002; 81(2): 99-103.
15. Ludlow JP, Evans SF, Hulse G. Obstetric and perinatal outcomes in pregnancies associated with illicit substance abuse. Aust N Z J Obstet Gynaecol 2004; 44(4): 302-306.
16. Euler GL, Wooten KG, Baughman AL, Williams WW. Hepatitis B surface antigen prevalence among pregnant women in urban areas: implications for testing, reporting, and preventing perinatal transmission. Pediatrics 2003; 111(5 Part 2): 1192-1197.
17. Beasley RP, Trepo C, Stevens CE, Szmuness W. The e antigen and vertical transmission of hepatitis B surface antigen. Am J Epidemiol 1977; 105(2): 94-98.
18. Okada K, Kamiyama I, Inomata M, Imai M, Miyakawa Y. e antigen and anti-e in the serum of asymptomatic carrier mothers as indicators of positive and negative transmission of hepatitis B virus to their infants. N Engl J Med 1976; 294 (14): 746-749.
19. Stevens CE, Neurath RA, Beasley RP, Szmuness W. HBeAg and anti-HBe detection by radioimmunoassay: correlation with vertical transmission of hepatitis B virus in Taiwan. J Med Virol 1979; 3(3): 237-241.
20. Keeffe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiff ER et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008; 6(12): 1315-1341.
21. ACOG educational bulletin. Viral hepatitis in pregnancy. Number 248, July 1998 (replaces No. 174, November 1992).
22. American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet 1998; 63(2): 195-202.
23. del Canho R, Grosheide PM, Schalm SW, de Vries RR, Heijtink RA. Failure of neonatal hepatitis B vaccination: the role of HBV-DNA levels in hepatitis B carrier mothers and HLA antigens in neonates. J Hepatol 1994; 20(4): 483-486.
24. Centers for Disease Control and Prevention (CDC). Assessing completeness of perinatal hepatitis B virus infection reporting through comparison of immunization program and surveillance data-United States. MMWR Morb Mortal Wkly Rep 2011; 60(13): 410-413.
25. Levy M, Koren G. Hepatitis B vaccine in pregnancy: maternal and fetal safety. Am J Perinatol 1991; 8(3): 227-232.
26. Ornoy A, Tenenbaum A. Pregnancy outcome following infections by coxsackie, echo, measles, mumps, hepatitis, polio and encephalitis viruses. Reprod Toxicol 2006; 21(4): 446-457.
27. Rawal BK, Parida S, Watkins RP, Ghosh P, Smith H. Symptomatic reactivation of hepatitis B in pregnancy. Lancet 1991; 337(8737): 364.
28. Lin HH, Chen PJ, Chen DS, Sung JL, Yang KH, Young YC et al. Postpartum subsidence of hepatitis B viral replication in HBeAg-positive carrier mothers. J Med Virol 1989; 29(1): 1-6.
29. Lin HH, Wu WY, Kao JH, Chen DS. Hepatitis B post-partum e antigen clearance in hepatitis B carrier mothers: Correlation with viral characteristics. J Gastroenterol Hepatol 2006; 21(3): 605-609.
30. ter Borg MJ, Leemans WF, de Man RA, Janssen HL. Exacerbation of chronic hepatitis B infection after delivery. J Viral Hepat 2008; 15(1): 37-41.
31. Libbus MK, Phillips LM. Public health management of perinatal hepatitis B virus. Public Health Nurs 2009; 26(4): 353-361.
32. Pan CQ, Duan ZP, Bhamidimarri KR, Zou HB, Liang XF, Li J et al. An algorithm for risk assessment and intervention of mother to child transmission of hepatitis B virus. Clin Gastroenterol Hepatol 2012; 10(5): 452-459.
33. van Zonneveld M, van Nunen AB, Niesters HG, de Man RA, Schalm SW, Janssen HL. Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J Viral Hepat 2003; 10(4): 294-297.
34. Xu DZ, Yan YP, Choi BC, Xu JQ, Men K, Zhang JX et al. Risk factors and mechanism of transplacental transmission of hepatitis B virus: a casecontrol study. J Med Virol 2002; 67(1): 20-26.
35. Xu WM, Cui YT, Wang L, Yang H, Liang ZQ, Li XM et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. J Viral Hepat 2009; 16(2): 94-103.
36. Zou H, Chen Y, Duan Z, Zhang H, Pan C. Virologic factors associated with failure to passive-active immunoprophylaxis in infants born to HBsAg-positive mothers. J Viral Hepat 2012; 19(2): e18-e25.
37. Alter MJ. Epidemiology of hepatitis B in Europe and worldwide. J Hepatol 2003; 39(Suppl 1): S64-S69.
38. Wang JS, Chen H, Zhu QR. Transformation of hepatitis B serologic markers in babies born to hepatitis B surface antigen positive mothers. World J Gastroenterol 2005; 11(23): 3582-3585.
39. Xu ZY, Duan SC, Margolis HS, Purcell RH, Ou-Yang PY, Coleman PJ et al. Longterm efficacy of active postexposure immunization of infants for prevention of hepatitis B virus infection. United States-People's Republic of China Study Group on Hepatitis B. J Infect Dis 1995; 171(1): 54-60.
40. Krugman S. Hepatitis B virus and the neonate. Ann NY Acad Sci 1988; 549: 129-134.
41. Beasley RP, Hwang LY, Stevens CE, Lin CC, Hsieh FJ, Wang KY et al. Efficacy of hepatitis B immune globulin for prevention of perinatal transmission of the hepatitis B virus carrier state: final report of a randomized double-blind, placebocontrolled trial. Hepatology 1983; 3(2): 135-141.
42. Schalm SW, Mazel JA, de Gast GC, Heijtink RA, Botman MJ, Banffer JR et al. Prevention of hepatitis B infection in newborns through mass screening and delayed vaccination of all infants of mothers with hepatitis B surface antigen. Pediatrics 1989; 83(6): 1041-1048.
43. Stevens CE, Toy PT, Tong MJ, Taylor PE, Vyas GN, Nair PV et al. Perinatal hepatitis B virus transmission in the United States. Prevention by passive-active immunization. JAMA 1985; 253(12): 1740-1745.
44. Lin HH, Lee TY, Chen DS, Sung JL, Ohto H, Etoh T et al. Transplacental leakage of HBeAg-positive maternal blood as the most likely route in causing intrauterine infection with hepatitis B virus. J Pediatr 1987; 111(6 Pt 1): 877-881.
45. Ohto H, Lin HH, Kawana T, Etoh T, Tohyama H. Intrauterine transmission of hepatitis B virus is closely related to placental leakage. J Med Virol 1987; 21(1): 1-6.
46. Ko TM, Tseng LH, Chang MH, Chen DS, Hsieh FJ, Chuang SM et al. Amniocentesis in mothers who are hepatitis B virus carriers does not expose the infant to an increased risk of hepatitis B virus infection. Arch Gynecol Obstet 1994; 255(1): 25-30.
47. Wang J, Zhu Q, Zhang X. Effect of delivery mode on maternal-infant transmission of hepatitis B virus by immunoprophylaxis. Chin Med J (Engl) 2002; 115(10): 1510-1512.
48. Andre FE, Zuckerman AJ. Review: protective efficacy of hepatitis B vaccines in neonates. J Med Virol 1994; 44(2): 144-151.
49. Stevens CE, Taylor PE, Tong MJ, Toy PT, Vyas GN, Nair PV et al. Yeast-recombinant hepatitis B vaccine. Efficacy with hepatitis B immune globulin in prevention of perinatal hepatitis B virus transmission. JAMA 1987; 257(19): 2612-2616.
50. Noto H, Terao T, Ryou S, Hirose Y, Yoshida T, Ookubo H et al. Combined passive and active immunoprophylaxis for preventing perinatal transmission of the hepatitis B virus carrier state in Shizuoka, Japan during 1980-1994. J Gastroenterol Hepatol 2003; 18(8): 943-949.
51. Soleimani Amiri MJ, Hasanjani Roushan MR, Baiany M, Taheri H, Hasanjani Roushan M. Outcomes of passive-active immunoprophylaxis given to infants of mothers infected with hepatitis B virus in Babol, Iran. J Clin Virol 2010; 49(4): 283-285.
52. Ip HM, Lelie PN, Wong VC, Kuhns MC, Reesink HW. Prevention of hepatitis B virus carrier state in infants according to maternal serum levels of HBV DNA. Lancet 1989; 1(8635): 406-410.
53. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339(2): 61-68.
54. Han GR, Cao MK, Zhao W, Jiang HX, Wang CM, Bai SF et al. A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. J Hepatol 2011; 55(6): 1215-1221.
55. Shi Z, Yang Y, Ma L, Li X, Schreiber A. Lamivudine in late pregnancy to interrupt in utero transmission of hepatitis B virus: a systematic review and meta-analysis. Obstet Gynecol 2010; 116(1): 147-159.
56. Su GG, Pan KH, Zhao NF, Fang SH, Yang DH, Zhou Y. Efficacy and safety of lamivudine treatment for chronic hepatitis B in pregnancy. World J Gastroenterol 2004; 10(6): 910-912.
57. Han L, Zhang HW, Xie JX, Zhang Q, Wang HY, Cao GW. A meta-analysis of lamivudine for interruption of mother-to-child transmission of hepatitis B virus. World J Gastroenterol 2011; 17(38): 4321-4333.
58. Peters MG. Special populations with hepatitis B virus infection. Hepatology 2009; 49(5 Suppl): S146-S155.
59. European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57(1): 167-185.
60. Pan CQ, Han GR, Jiang HX, Zhao W, Cao MK, Wang CM et al. Telbivudine prevents vertical transmission from HBeAg-positive women with chronic hepatitis B. Clin Gastroenterol Hepatol 2012; 10(5): 520-526.
61. Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology 2009; 49(5 Suppl): S185-S195.
62. Benaboud S, Pruvost A, Coffie PA, Ekouevi DK, Urien S, Arrive E et al. Concentrations of tenofovir and emtricitabine in breast milk of HIV-1-infected women in Abidjan, Cote d'Ivoire, in the ANRS 12109 TEmAA Study, Step 2. Antimicrob Agents Chemother 2011; 55(3): 1315-1317.
63. Pan CQ, Mi LJ, Bunchorntavakul C, Karsdon J, Huang WM, Singhvi G et al. Tenofovir disoproxil fumarate for prevention of vertical transmission of hepatitis B virus infection by highly viremic pregnant women: a case series. Dig Dis Sci 2012; 57(9): 2423-2429.
64. Liaw YF, Kao JH, Piratvisuth T, Chan HLY, Chien RN, Liu CJ et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012; 6(3): 531-561.
65. Yang J, Zeng XM, Men YL, Zhao LS. Elective caesarean section versus vaginal delivery for preventing mother to child transmission of hepatitis B virus-a systematic review. Virol J 2008; 5: 100.
66. Pan CQ, Zou HB, Chen Y, Zhang XH, Zhang H, Li J et al. Cesarean section reduces perinatal transmission of hepatitis B virus infection from hepatitis B surface antigen-positive women to their infants. Clini Gastroenterol Hepatol 2013; 11(10): 1349-1355.
67. Wong VC, Lee AK, Ip HM. Transmission of hepatitis B antigens from symptom free carrier mothers to the fetus and the infant. Br J Obstet Gynaecol 1980; 87(11): 958-965.
68. Beasley RP, Stevens CE, Shiao IS, Meng HC. Evidence against breast-feeding as a mechanism for vertical transmission of hepatitis B. Lancet 1975; 2(7938): 740-741.
69. Gartner LM, Morton J, Lawrence RA, Naylor AJ, O'Hare D, Schanler RJ et al. Breastfeeding and the use of human milk. Pediatrics 2005; 115(2): 496-506.
70. Alter MJ. Epidemiology of hepatitis C. Hepatology 1997; 26(3 Suppl 1): 62S-65S.
71. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341(8): 556-562.
72. Yeung LT, King SM, Roberts EA. Mother-to-infant transmission of hepatitis C virus. Hepatology 2001; 34(2): 223-229.
73. Jonas MM. Hepatitis C infection in children. N Engl J Med 1999; 341(12): 912-913.
74. Zanetti AR, Tanzi E, Newell ML. Mother-to-infant transmission of hepatitis C virus. J Hepatol 1999; 31(Suppl 1): 96-100.
75. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002-June 10-12, 2002. Hepatology 2002; 36(5 Suppl 1): S3-20.
76. Roberts EA, Yeung L. Maternal-infant transmission of hepatitis C virus infection. Hepatology 2002; 36(5 Suppl 1): S106-S113.
77. Conte D, Fraquelli M, Prati D, Colucci A, Minola E. Prevalence and clinical course of chronic hepatitis C virus (HCV) infection and rate of HCV vertical transmission in a cohort of 15, 250 pregnant women. Hepatology 2000; 31(3): 751-755.
78. Gervais A, Bacq Y, Bernuau J, Martinot M, Auperin A, Boyer N et al. Decrease in serum ALT and increase in serum HCV RNA during pregnancy in women with chronic hepatitis C. J Hepatol 2000; 32(2): 293-299.
79. Wegmann TG, Lin H, Guilbert L, Mosmann TR. Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon? Immunol Today 1993; 14(7): 353-356.
80. Lee RH, Goodwin TM, Greenspoon J, Incerpi M. The prevalence of intrahepatic cholestasis of pregnancy in a primarily Latina Los Angeles population. J Perinatol 2006; 26(9): 527-532.
81. Ohto H, Terazawa S, Sasaki N, Hino K, Ishiwata C, Kako M et al. Transmission of hepatitis C virus from mothers to infants. The Vertical Transmission of Hepatitis C Virus Collaborative Study Group. N Engl J Med 1994; 330(11): 744-750.
82. Ferrero S, Lungaro P, Bruzzone BM, Gotta C, Bentivoglio G, Ragni N. Prospective study of mother-to-infant transmission of hepatitis C virus: a 10-year survey (1990-2000). Acta Obstet Gynecol Scand 2003; 82(3): 229-234.
83. Ruiz-Extremera A, Munoz-Gamez JA, Salmeron-Ruiz MA, de Rueda PM, Quiles-Perez R, Gila-Medina A et al. Genetic variation in interleukin 28B with respect to vertical transmission of hepatitis C virus and spontaneous clearance in HCV-infected children. Hepatology 2011; 53(6): 1830-1838.
84. Bortolotti F, Verucchi G, Camma C, Cabibbo G, Zancan L, Indolfi G et al. Longterm course of chronic hepatitis C in children: from viral clearance to end-stage liver disease. Gastroenterology 2008; 134(7): 1900-1907.
85. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461(7265): 798-801.
86. Thomas DL, Villano SA, Riester KA, Hershow R, Mofenson LM, Landesman SH et al. Perinatal transmission of hepatitis C virus from human immunodeficiency virus type 1-infected mothers. Women and Infants Transmission Study. J Infect Dis 1998; 177(6): 1480-1488.
87. Thaler MM, Park CK, Landers DV, Wara DW, Houghton M, Veereman-Wauters G et al. Vertical transmission of hepatitis C virus. Lancet 1991; 338(8758): 17-18.
88. Zanetti AR, Tanzi E, Paccagnini S, Principi N, Pizzocolo G, Caccamo ML et al. Mother-to-infant transmission of hepatitis C virus. Lombardy Study Group on Vertical HCV Transmission. Lancet 1995; 345(8945): 289-291.
89. Mast EE, Hwang LY, Seto DS, Nolte FS, Nainan OV, Wurtzel H et al. Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. J Infect Dis 2005; 192(11): 1880-1889.
90. Steininger C, Kundi M, Jatzko G, Kiss H, Lischka A, Holzmann H. Increased risk of mother-to-infant transmission of hepatitis C virus by intrapartum infantile exposure to maternal blood. J Infect Dis 2003; 187(3): 345-351.
91. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm Rep 1998; 47(RR-19): 1-39.
92. European Paediatric Hepatitis C Virus Network. Effects of mode of delivery and infant feeding on the risk of mother-to-child transmission of hepatitis C virus. European Paediatric Hepatitis C Virus Network. BJOG 2001; 108(4): 371-377.
93. McIntyre PG, Tosh K, McGuire W. Caesarean section versus vaginal delivery for preventing mother to infant hepatitis C virus transmission. Cochrane Database Syst Rev 2006; 4: CD005546.
94. Gibb DM, Goodall RL, Dunn DT, Healy M, Neave P, Cafferkey M et al. Mother-tochild transmission of hepatitis C virus: evidence for preventable peripartum transmission. Lancet 2000; 356(9233): 904-907.
95. Ghamar Chehreh ME, Tabatabaei SV, Khazanehdari S, Alavian SM. Effect of cesarean section on the risk of perinatal transmission of hepatitis C virus from HCV-RNA?mothers: a meta-analysis. Arch Gynecol Obstet 2011; 283(2): 255-260.
96. Polywka S, Schroter M, Feucht HH, Zollner B, Laufs R. Low risk of vertical transmission of hepatitis C virus by breast milk. Clin Infect Dis 1999; 29(5): 1327-1329.
97. Kumar RM, Shahul S. Role of breast-feeding in transmission of hepatitis C virus to infants of HCV-infected mothers. J Hepatol 1998; 29(2): 191-197.
98. Resti M, Azzari C, Mannelli F, Moriondo M, Novembre E, de Martino M et al. Mother to child transmission of hepatitis C virus: prospective study of risk factors and timing of infection in children born to women seronegative for HIV-1. Tuscany Study Group on Hepatitis C Virus Infection. BMJ 1998; 317(7156): 437-441.
99. Thomas SL, Newell ML, Peckham CS, Ades AE, Hall AJ. A review of hepatitis C virus (HCV) vertical transmission: risks of transmission to infants born to mothers with and without HCV viraemia or human immunodeficiency virus infection. Int J Epidemiol 1998; 27(1): 108-117.
100. ACOG committee opinion. Breastfeeding and the risk of hepatitis C virus transmission. Number 220, August 1999.
101. Committee on Obstetric Practice. American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet 1999; 66(3): 307-308.
102. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368(20): 1878-1887.
103. Jesudian AB, de Jong YP, Jacobson IM. Emerging therapeutic targets for hepatitis C virus infection. Clin Gastroenterol Hepatol 2013; 11(6): 612-619, e611.
104. Schmidt WN, Nelson DR, Pawlotsky JM, Sherman KE, Thomas DL, Chung RT. Direct-acting antiviral agents and the path to interferon independence. Clin Gastroenterol Hepatol 2013; 12(5): 728-737.
105. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014; 370(3): 211-221.
106. Kowdley KV, Lawitz E, Poordad F, Cohen DE, Nelson DR, Zeuzem S et al. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med 2014; 370(3): 222-232.
107. Schmidt WN, Nelson DR, Pawlotsky JM, Sherman KE, Thomas DL, Chung RT. Direct-acting antiviral agents and the path to interferon independence. Clin Gastroenterol Hepatol 2014; 12(5): 728-737.
108. Sulkowski MS. Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection. New Engl J Med 2014; 370(15): 1469-1469.
109. Poland GA, Jacobson RM. Clinical practice: prevention of hepatitis B with the hepatitis B vaccine. N Engl J Med 2004; 351(27): 2832-2838.